More frequent lab tests will be recommended for patients taking Arava (leflunomide)

January 2004

More frequent lab tests will be recommended for patients taking Arava (leflunomide).

This is due to potential hepatotoxicity or severe infections due to immunosuppression.

The biggest concern is for patients with other risk factors for hepatotoxicity or immunosuppression.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

alternatives to prevent or treat flu
single-ingredient, extended-release guaifenesin products
A simple new technique might help patients who get nosebleeds from nasal steroids
Men's Health Cialis for erectile dysfunction
Men's Health some medications can worsen urinary symptoms
Diabetes More people will be labeled as having "pre-diabetes"
Women's Health big push to increase access to emergency contraceptives
Women's Health Climara Pro, a new COMBINATION estrogen and progestin patch for relieving menopausal symptoms
Risperdal (risperidone) is now approved for acute mania
Obesity & Weight Loss what works for weight loss
More frequent lab tests will be recommended for patients taking Arava (leflunomide)
FLUIDjoint, a new supplement for osteoarthritis
Hematology & Oncology potential interaction between tamoxifen and paroxetine (Paxil)
Hematology & Oncology Plenaxis (abarelix), a new drug for advanced prostate cancer
Cardiology Spironolactone will be used more for hypertension
Practice The new Medicare drug program